CL2021002986A1 - Compuestos anticancerígenos dirigidos a los receptores de hormonas nucleares - Google Patents

Compuestos anticancerígenos dirigidos a los receptores de hormonas nucleares

Info

Publication number
CL2021002986A1
CL2021002986A1 CL2021002986A CL2021002986A CL2021002986A1 CL 2021002986 A1 CL2021002986 A1 CL 2021002986A1 CL 2021002986 A CL2021002986 A CL 2021002986A CL 2021002986 A CL2021002986 A CL 2021002986A CL 2021002986 A1 CL2021002986 A1 CL 2021002986A1
Authority
CL
Chile
Prior art keywords
anticancer compounds
hormone receptors
nuclear hormone
compounds targeting
targeting nuclear
Prior art date
Application number
CL2021002986A
Other languages
English (en)
Inventor
David Hung
Son Minh Pham
Sarvajit Chakravarty
Jiyun Chen
Jayakanth Kankanala
Jeremy D Pettigrew
Anup Barde
Anjan Kumar Nayak
Original Assignee
Nuvation Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvation Bio Inc filed Critical Nuvation Bio Inc
Publication of CL2021002986A1 publication Critical patent/CL2021002986A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La divulgación se refiere a compuestos anticancerígenos derivados de ligantes de receptores de esteroides nucleares, a productos que contienen los mismos, así como a métodos de su uso y preparación.
CL2021002986A 2019-05-14 2021-11-12 Compuestos anticancerígenos dirigidos a los receptores de hormonas nucleares CL2021002986A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962847854P 2019-05-14 2019-05-14
US201962935069P 2019-11-13 2019-11-13
US201962938218P 2019-11-20 2019-11-20

Publications (1)

Publication Number Publication Date
CL2021002986A1 true CL2021002986A1 (es) 2022-09-23

Family

ID=73230939

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002986A CL2021002986A1 (es) 2019-05-14 2021-11-12 Compuestos anticancerígenos dirigidos a los receptores de hormonas nucleares

Country Status (13)

Country Link
US (1) US11826430B2 (es)
EP (1) EP3969050A4 (es)
JP (1) JP2022532342A (es)
KR (1) KR20220008869A (es)
CN (1) CN113811333B (es)
AU (1) AU2020274113A1 (es)
BR (1) BR112021022008A2 (es)
CA (1) CA3138197A1 (es)
CL (1) CL2021002986A1 (es)
IL (1) IL287911A (es)
MX (1) MX2021013774A (es)
SG (1) SG11202111402PA (es)
WO (1) WO2020232119A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019344783A1 (en) 2018-09-17 2021-04-08 The Children's Hospital Of Philadelphia Polymer-based macromolecular prodrugs
CN114072414A (zh) * 2019-04-27 2022-02-18 健康研究股份有限公司 用于治疗前列腺癌的香豆素修饰的雄激素
CA3138197A1 (en) 2019-05-14 2020-11-19 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP4058464A1 (en) * 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN114516877B (zh) * 2020-11-20 2023-10-27 烟台弘邦医药科技有限公司 一种瑞卡帕布中间体的制备方法
CN113024513A (zh) * 2021-03-22 2021-06-25 中国药科大学 新型雄激素受体降解剂、制备方法和医药用途
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
IL308104A (en) 2021-05-03 2023-12-01 Nuvation Bio Inc Nuclear hormone receptor-targeted compounds against cancer
CN113788827B (zh) * 2021-10-18 2023-04-25 中国药科大学 酞嗪酮类化合物及其制备方法和医药用途

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3907290A1 (de) 1989-03-07 1990-09-13 Gerhard Prof Dr Eisenbrand Steroidhormonrezeptoraffine antitumorwirkstoffe
WO1996000090A1 (en) 1994-06-27 1996-01-04 Ionix Corporation Boron-containing hormone analogs and methods of their use in imaging or killing cells having hormone receptors
CN1172502A (zh) 1994-08-12 1998-02-04 亿万遗传股份有限公司 17q连锁的乳房癌和卵巢癌易患性基因的体内突变和多态性
EP0699754B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Method for diagnosing a predisposition for breast and ovarian cancer
DE69534551T2 (de) 1994-11-01 2006-06-22 Ariad Gene Therapeutics, Inc., Cambridge Neue Methode zum Auffinden und Bewerten biologisch aktiver Moleküle
US20030059465A1 (en) 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
AU778655B2 (en) 1999-08-27 2004-12-16 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
KR100826485B1 (ko) 1999-10-14 2008-05-02 가켄 세야쿠 가부시키가이샤 테트라히드로퀴놀린 유도체
US7038041B2 (en) 2000-04-12 2006-05-02 The Trustees Of Boston University Selective nuclear receptor-targeted systems for delivery of cytotoxins to cancer cells for targeted photodynamic therapy
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US6777427B2 (en) 2000-09-14 2004-08-17 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinoline compounds
CA2463311A1 (en) 2001-10-19 2003-05-01 Paul J. Coleman Androgen receptor modulators and methods of use thereof
IL148825A0 (en) 2002-03-21 2002-09-12 Yeda Res & Dev Derivatives of isoflavones
ITRM20020305A1 (it) 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Camptotecine con anello lattonico modificato.
WO2004000816A1 (ja) 2002-06-19 2003-12-31 Kaken Pharmaceutical Co., Ltd. アンドロゲン受容体アゴニスト
EP1541560A4 (en) 2002-08-01 2007-03-21 Kaken Pharma Co Ltd NEW TETRAHYDROCHINOLINE DERIVATIVES
WO2004041277A1 (en) 2002-11-01 2004-05-21 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
EA009469B1 (ru) 2003-03-12 2007-12-28 Кудос Фармасеутикалс Лимитед Производные фталазинона
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
JP4578470B2 (ja) 2003-04-22 2010-11-10 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ ソマトスタチンベクター
JP2007505164A (ja) 2003-06-10 2007-03-08 スミスクライン ビーチャム コーポレーション アンドロゲン、グルココルチコイド、ミネラルコルチコイドおよびプロゲステロン受容体のモジュレーターとしての１−アミノナフタレン類
US20060148893A1 (en) 2003-06-10 2006-07-06 Blanc Jean-Baptiste E Chemical compounds
AU2004249697B2 (en) 2003-06-13 2010-04-22 Janssen Pharmaceutica N.V. Thiazoline derivatives as selective androgen receptor modulators (SARMS)
WO2005034856A2 (en) 2003-09-05 2005-04-21 The Regents Of The University Of Colorado Targeted drug-formaldehyde conjugates and methods of making and using the same
US7220730B2 (en) 2003-09-25 2007-05-22 Board Of Regents Of The University Of Nebraska Cancer specific radiolabeled conjugates regulated by the cell cycle for the treatment and diagnosis of cancer
DK2305221T3 (en) * 2003-12-01 2015-08-24 Kudos Pharm Ltd DNA damage repair inhibitors for the treatment of cancer
JP4805909B2 (ja) 2004-03-03 2011-11-02 スミスクライン ビーチャム コーポレーション 選択的アンドロゲン受容体モジュレーターとしてのアニリン誘導体
CA2601038A1 (en) 2004-03-10 2005-09-22 Massachusetts Institute Of Technology Methods and compositions for treating cancer
EP1756109B1 (en) 2004-05-03 2016-07-13 Janssen Pharmaceutica NV Novel indole derivatives as selective androgen receptor modulators (sarms)
US7282507B2 (en) 2004-05-03 2007-10-16 Janssen Pharmaceutica N.V. Indole derivatives as selective androgen receptor modulators (SARMS)
US20080045504A1 (en) 2004-05-11 2008-02-21 Pfizer Products Inc. Benzonitrile Derivatives to Treat Musculoskeletal Frailty
JP2007538085A (ja) 2004-05-17 2007-12-27 アカディア ファーマシューティカルズ インコーポレイティド アンドロゲン受容体モジュレーターおよびそれを用いて疾患を治療する方法
WO2005118612A1 (en) 2004-06-04 2005-12-15 Sonus Pharmaceuticals, Inc. Cholesterol/bile acid/bile acid derivative-modified therapeutic anti-cancer drugs
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
JP5031568B2 (ja) 2004-09-10 2012-09-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドロゲン受容体モジュレーター（ｓａｒｍｓ）としての新規なイミダゾリジン−２−オン誘導体
EP1809275A1 (en) 2004-10-13 2007-07-25 Smithkline Beecham Corporation Chemical compounds
EP1807076A4 (en) 2004-10-29 2010-06-02 Merck Sharp & Dohme N- (PYRIDIN-3-YL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS
WO2006055184A2 (en) 2004-11-16 2006-05-26 Janssen Pharmaceutica N.V. Novel heterocycle derivatives useful as selective androgen receptor modulators (sarms)
KR20070112775A (ko) 2005-01-10 2007-11-27 아카디아 파마슈티칼스 인코포레이티드 선택적인 안드로겐 수용체 조절자로서의 아미노페닐 유도체
JP5089578B2 (ja) 2005-05-13 2012-12-05 イーライ リリー アンド カンパニー 選択的なアンドロゲン受容体調節物質としての置換型ｎ−アリールピロリジン
WO2006133216A2 (en) 2005-06-06 2006-12-14 Smithkline Beecham Corporation 4-substituted arylamine derivatives and their use in pharmaceutical compositions
MX2007015905A (es) 2005-06-24 2008-03-06 Lilly Co Eli Derivados de tetrahidrocarbazol utiles como moduladores de receptor de androgeno (sarm).
US20070122843A1 (en) 2005-09-23 2007-05-31 Fazlul Sarkar Isoflavonoid analogs and their metal complexes as anti-cancer agents
GB0701273D0 (en) 2007-01-24 2007-02-28 Angeletti P Ist Richerche Bio New compounds
WO2009005839A2 (en) 2007-07-03 2009-01-08 The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Service Compounds and methods of use
US20090062268A1 (en) 2007-08-27 2009-03-05 Lead Therapeutics, Inc. Novel inhibitors of poly(adp-ribose)polymerase (parp)
GB0718045D0 (en) 2007-09-14 2007-10-24 Peptcell Ltd Pharmaceutical compound
US8184109B2 (en) * 2007-10-24 2012-05-22 Wacom Co., Ltd. Coordinate input device, position indicator and variable capacitor
JP2011503111A (ja) 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
US20090257999A1 (en) * 2007-12-31 2009-10-15 Inotek Pharmaceuticals Corporation Method of preventing contrast-induced nephropathy
AR070221A1 (es) * 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2009114459A2 (en) * 2008-03-10 2009-09-17 The Trustees Of The University Of Pennsylvania Anti-neoplastic combination therapeutic regimen involving co-disruption of parp pathway and mre11/rad50/nbs1 complex and compositons useful therein
US20110028420A1 (en) * 2008-04-10 2011-02-03 Boulares Hamid A Regression of Established Atherosclerotic Plaques, and Treating Sudden-Onset Asthma Attacks, using PARP Inhibitors
WO2009155431A1 (en) 2008-06-18 2009-12-23 University Of Louisville Research Foundation, Inc. Methods for targeted cancer treatment and detection
NZ591166A (en) 2008-08-06 2012-11-30 Biomarin Pharm Inc Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
US20110053923A1 (en) 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
US20120046461A1 (en) 2009-01-23 2012-02-23 Northeastern University Steroidal anti-hormone hybrids
BRPI0901157A2 (pt) 2009-03-27 2010-11-16 Univ Fed Pernambuco complexo molecular antineoplásico-testosterona
CA2775266C (en) 2009-10-13 2013-12-31 Duquesne University Of The Holy Spirit, A Nonprofit Corporation Organized Under The Laws Of The Commonwealth Of Pennsylvania Anti-cancer tamoxifen-melatonin hybrid ligand
CN102985443B (zh) 2010-04-16 2017-05-10 动量制药公司 组织靶向
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
JP2013532683A (ja) 2010-07-27 2013-08-19 カディラ ヘルスケア リミティド ポリ（ａｄｐリボース）ポリメラーゼ−１阻害剤としての、置換４−（４−フルオロ−３−（ピペラジン−１−カルボニル）ベンジル）フタラジン−１（２ｈ）−オン誘導体
CN101967172A (zh) 2010-09-15 2011-02-09 东北林业大学 喜树碱10位偶合胆酸的新衍生物
CN101967173A (zh) 2010-09-15 2011-02-09 东北林业大学 喜树碱10位偶合胆酸的新衍生物
CN101948500A (zh) 2010-09-15 2011-01-19 东北林业大学 喜树碱20位偶合胆酸的新衍生物
WO2012050868A1 (en) 2010-09-28 2012-04-19 Georgia Tech Research Corporation Histone deacetylase (hdac) inhibitors targeting prostate tumors and methods of making and using thereof
US9649394B2 (en) 2010-11-22 2017-05-16 The General Hospital Corporation Compositions and methods for in vivo imaging
MX2013010530A (es) * 2011-03-14 2014-05-01 Univ British Columbia Combinacion de oligonucleotido anti-clusterina con antagonistas del receptor de androgeno para el tratamiento de cancer de prostata.
WO2012134446A1 (en) 2011-03-29 2012-10-04 SUTTER WEST BAY HOSPITALS doing business as CALIFORNIA PACIFIC MEDICAL CENTER Epiandrosterone and/or androsterone derivatives and method of use thereof
WO2013028495A1 (en) 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
JP5934986B2 (ja) 2011-09-07 2016-06-15 公益財団法人ヒューマンサイエンス振興財団 アポトーシス阻害タンパク質リガンド−エストロゲン受容体リガンドハイブリッド化合物並びにそれを利用したエストロゲン受容体分解誘導剤及び乳癌、子宮頚癌又は卵巣癌の予防及び治療剤
CN102492010A (zh) 2011-12-15 2012-06-13 东北林业大学 喜树碱20位胆酸衍生物及其制备方法
CN102492009A (zh) 2011-12-15 2012-06-13 东北林业大学 喜树碱20位胆酸衍生物及其制备方法
CN102516347A (zh) 2011-12-15 2012-06-27 东北林业大学 喜树碱20位胆酸衍生物及其制备方法
CN102532237A (zh) 2011-12-15 2012-07-04 东北林业大学 喜树碱10位胆酸偶合物及其制备方法
CA2861066C (en) 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
US9556167B2 (en) 2012-05-02 2017-01-31 Yale University TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs)
CN104582732A (zh) 2012-06-15 2015-04-29 布里格姆及妇女医院股份有限公司 治疗癌症的组合物及其制造方法
US11873281B2 (en) 2012-07-12 2024-01-16 Hangzhou Dac Biotech Co., Ltd. Conjugates of cell binding molecules with cytotoxic agents
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en) * 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
GB201311910D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel Compounds
EP3360875A1 (en) 2013-05-28 2018-08-15 Astrazeneca AB Chemical compounds
WO2014201026A2 (en) 2013-06-10 2014-12-18 Cedars-Sinai Medical Center Antioxidant, anti-inflammatory and anticancer derivatives of triptolide and nanospheres thereof
CN104292290A (zh) 2013-07-16 2015-01-21 中国人民解放军军事医学科学院毒物药物研究所 以氨基酸为连接子的胆汁酸-药物偶合物及其医药用途
WO2015038649A1 (en) 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Targeted therapeutics
IL290330B2 (en) 2013-12-19 2023-09-01 Seagen Inc Methylene carbamate binders for use with drug-targeting conjugates
WO2015134464A2 (en) 2014-03-03 2015-09-11 Synta Pharmaceuticals Corp. Targeted therapeutics
EP3131586A4 (en) 2014-03-18 2017-10-25 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN105315294B (zh) 2014-06-26 2018-05-01 王杭祥 7-乙基-10-羟基喜树碱药物前体及其制备方法和应用
WO2016025480A1 (en) 2014-08-11 2016-02-18 The General Hospital Corporation Cyclooctenes for bioorthogonol reactions
MX2017006016A (es) 2014-11-11 2017-06-19 Amunix Operating Inc Composiciones conjugadas de xten direccionadas y metodos para producir las mismas.
MA53837A (fr) 2014-12-18 2021-11-10 Hoffmann La Roche Tetrahydro-pyrido[3,4-b]indoles modulateurs des récepteurs des oestrogènes et leurs utilisations
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
KR20220029783A (ko) 2015-01-20 2022-03-08 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
MX2017011919A (es) 2015-03-18 2018-05-22 Arvinas Inc Compuestos y metodos para la degradacion mejorada de proteinas especificas.
KR102664618B1 (ko) * 2015-05-29 2024-05-10 에자이 알앤드디 매니지먼트 가부시키가이샤 사치환된 알켄 화합물 및 그의 용도
EP3302572B8 (en) 2015-06-04 2021-03-24 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
EP3302482A4 (en) 2015-06-05 2018-12-19 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
WO2015151078A2 (en) 2015-06-15 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Hydrophilic linkers for conjugation
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
CA2991384C (en) 2015-07-04 2022-11-08 Suzhou M-Conj Biotech Co., Ltd Bridge linkers for conjugation of a cell-binding molecule
AU2016291578C1 (en) 2015-07-10 2021-07-15 Arvinas Operations, Inc. MDM2-based modulators of proteolysis and associated methods of use
EP3319936A4 (en) 2015-07-12 2019-02-06 Suzhou M-conj Biotech Co., Ltd. PLACES OF CONDUCT FOR THE CONJUGATION OF CELL BINDING MOLECULES
RU2018105094A (ru) 2015-07-13 2019-08-14 Арвинас, Инк. Модуляторы протеолиза на основе аланина и связанные с ними способы применения
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CA2991975C (en) 2015-08-10 2021-04-06 Suzhou M-Conj Biotech Co., Ltd. Novel linkers and their uses in specific conjugation of drugs to a biological molecule
CN108366996B (zh) * 2015-10-01 2021-04-09 奥列马制药公司 四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物
US9963433B2 (en) 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
AU2016202632B2 (en) 2016-02-04 2021-09-09 Hangzhou Dac Biotech Co, Ltd Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
JP2019094260A (ja) 2016-03-28 2019-06-20 国立大学法人東北大学 癌疾患治療用ナノ粒子化製剤
CN107286166B (zh) 2016-04-11 2020-03-31 上海勋和医药科技有限公司 取代1，3，4，5-四氢-6h-吡咯并[4，3，2-ef][2]苯并氮杂-6-酮衍生物
GB201608885D0 (en) * 2016-05-20 2016-07-06 Univ Birmingham Treatment
AU2017277949B2 (en) 2016-06-09 2023-01-12 Blinkbio, Inc. Silanol based therapeutic payloads
TW201815789A (zh) * 2016-07-25 2018-05-01 瑞典商阿斯特捷利康公司 化合物
US10054602B2 (en) 2016-08-19 2018-08-21 Christ University Conjugate of estradiol and applications thereof
JP6997172B2 (ja) * 2016-08-24 2022-01-17 サイノファーム タイワン，リミティド オラパリブの製造方法
CN110506039A (zh) 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
JP7184775B2 (ja) 2016-12-14 2022-12-06 パーデュー・リサーチ・ファウンデイション 黄体化ホルモン放出ホルモン受容体（ｌｈｒｈ－ｒ）コンジュゲートおよびその使用
KR102564201B1 (ko) 2016-12-23 2023-08-07 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
CN110545846A (zh) 2017-02-23 2019-12-06 乐天医药生技股份有限公司 用于光免疫疗法的治疗组合物和相关方法
EA201992081A1 (ru) 2017-04-06 2020-01-21 Ханчжоу Дэк Биотек Ко., Лтд Конъюгирование цитотоксических лекарственных средств посредством бис-связывания
JP7320455B2 (ja) 2017-06-21 2023-08-03 グリコス・フィンランド・オーワイ 親水性リンカーおよびそのコンジュゲート
CN107266520A (zh) 2017-06-28 2017-10-20 湖南华腾制药有限公司 一种喜树碱与桦木酸结合物及其制备方法
WO2019023553A1 (en) 2017-07-28 2019-01-31 Arvinas, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR
CN108014347B (zh) 2017-11-23 2021-05-04 金志明 一种谷氨酸多肽-雌激素/抗雌激素缀合物、合成方法、组合物及试剂盒
US10519152B2 (en) * 2017-12-21 2019-12-31 Astrazeneca Ab Compounds and their use in treating cancer
CA3134610A1 (en) 2018-04-09 2019-10-17 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
CN112262134B (zh) 2018-04-13 2024-05-24 阿尔维纳斯运营股份有限公司 小脑蛋白配体和包括其的双官能化合物
WO2019222272A1 (en) * 2018-05-14 2019-11-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2019241231A1 (en) 2018-06-11 2019-12-19 Abhishek Sharma Antiestrogen compounds
US20200038513A1 (en) 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
US11478493B2 (en) 2019-03-08 2022-10-25 University Of South Carolina Fabrication and application of a hetero-targeted nano-cocktail with traceless linkers
US20200297725A1 (en) 2019-03-22 2020-09-24 Yale University Allosteric bcr-abl proteolysis targeting chimeric compounds
CA3138197A1 (en) 2019-05-14 2020-11-19 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN114040779A (zh) 2019-06-24 2022-02-11 杭州多禧生物科技有限公司 含支链连接子的细胞结合分子与细胞毒性剂的偶联物
UY38793A (es) 2019-07-19 2021-02-26 Astrazeneca Ab Compuestos químicos
EP4031543A4 (en) 2019-09-18 2023-09-27 The Regents Of The University Of California BIAMINOQUINOLINES AND NANOFORMULATIONS FOR THE TREATMENT OF CANCER
EP4058464A1 (en) 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
KR20220119094A (ko) 2019-12-19 2022-08-26 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
MX2022015598A (es) 2020-06-19 2023-02-01 Hangzhou Dac Biotech Co Ltd Conjugados de una molecula de union celular con analogos de camptotecina.
EP4196166A2 (en) 2020-08-11 2023-06-21 Peptinovo Biopharma Inc. Peptides and formulations for cancer treatment
WO2022040635A1 (en) 2020-08-21 2022-02-24 The University Of Chicago Nanoparticles containing multiple cleavable produgs for cancer therapy
AU2021365850A1 (en) 2020-10-21 2023-06-08 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor protein
JP2023548540A (ja) 2020-11-06 2023-11-17 アルビナス・オペレーションズ・インコーポレイテッド アンドロゲン受容体の標的分解のための化合物及び方法、並びに関連する使用方法
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
IL308104A (en) 2021-05-03 2023-12-01 Nuvation Bio Inc Nuclear hormone receptor-targeted compounds against cancer

Also Published As

Publication number Publication date
CA3138197A1 (en) 2020-11-19
MX2021013774A (es) 2021-12-10
BR112021022008A2 (pt) 2022-05-17
US20200360523A1 (en) 2020-11-19
AU2020274113A1 (en) 2021-11-11
KR20220008869A (ko) 2022-01-21
WO2020232119A1 (en) 2020-11-19
EP3969050A1 (en) 2022-03-23
US11826430B2 (en) 2023-11-28
EP3969050A4 (en) 2023-11-01
IL287911A (en) 2022-01-01
CN113811333B (zh) 2024-03-12
CN113811333A (zh) 2021-12-17
SG11202111402PA (en) 2021-11-29
JP2022532342A (ja) 2022-07-14

Similar Documents

Publication Publication Date Title
CL2021002986A1 (es) Compuestos anticancerígenos dirigidos a los receptores de hormonas nucleares
MX2020012066A (es) Compuestos anticancerígenos dirigidos a los receptores hormonales nucleares.
CO2023012534A2 (es) Compuestos dirigidos a receptores de hormonas nucleares contra el cáncer
CL2020002801A1 (es) Anticuerpos monoclonales contra bcma (divisional de solicitud 201800281).
DOP2017000298A (es) Reguladores de nrf2
DOP2016000145A (es) Reguladores de nrf2
CO2018003452A2 (es) Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
ECSP19000157A (es) Conjugados de anticuerpo y fármaco anti-egfr
DOP2018000082A (es) NUEVOS DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CR20140185A (es) Derivados de (4-fenilimidazol-2-il)etilamina útiles como moduladores de canal de sodio
UY37410A (es) Antagonistas de trpv4
CL2023002048A1 (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
CL2018001210A1 (es) Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico.
ECSP21090414A (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
CR20130671A (es) Antagonistas de trpv4
DOP2019000290A (es) Inhibidores de quinasa y usos de los mismos
BR112018075645A2 (pt) conjugados de anticorpo fármaco anti-egfr
BR112018075639A2 (pt) conjugados de anticorpo fármaco anti-egfr
CO2019009035A2 (es) Proteínas de unión al receptor de glucagón y métodos para usarlas
CL2019001991A1 (es) Moduladores del receptor de estrógeno.
CO7240378A2 (es) Indolcarbonitrilos como moduladores selectivos de los receptores de andrógeno
CR20160084A (es) Derivados de amida como agonistas del receptor del ácido lisofosfatídico
BR112016027133A8 (pt) derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso
MX2016001519A (es) Derivados de 25-oh vitamina d para determinacion de metabolitos de vitamina d.